8SV9
Crystal structure of ULK1 kinase domain with inhibitor MR-2088
8SV9 の概要
エントリーDOI | 10.2210/pdb8sv9/pdb |
分子名称 | Serine/threonine-protein kinase ULK1, (4P)-4-[(2P)-2-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide, SULFATE ION, ... (5 entities in total) |
機能のキーワード | autophagy, inhibitor, complex, kinase, transferase, transferase-inhibitor complex, transferase/inhibitor |
由来する生物種 | Homo sapiens (human) |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 65735.31 |
構造登録者 | |
主引用文献 | Morozova, A.,Chan, S.C.,Bayle, S.,Sun, L.,Grassie, D.,Iermolaieva, A.,Kalaga, M.N.,Frydman, S.,Sansil, S.,Schonbrunn, E.,Duckett, D.,Monastyrskyi, A. Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties. Eur.J.Med.Chem., 266:116101-116101, 2024 Cited by PubMed Abstract: The UNC-51-like kinase-1 (ULK1) is one of the central upstream regulators of the autophagy pathway, represents a key target for the development of molecular probes to abrogate autophagy and explore potential therapeutic avenues. Here we report the discovery, structure-activity and structure-property relationships of selective, potent, and cell-active ULK1/2 inhibitors based on a 7-azaindole scaffold. Using structure-based drug design, we have developed a series of analogs with excellent binding affinity and biochemical activity against ULK1/2 (IC < 25 nM). The validation of cellular target engagement for these compounds was achieved through the employment of the ULK1 NanoBRET intracellular kinase assay. Notably, we have successfully solved the crystal structure of the lead compound, MR-2088, bound to the active site of ULK1. Moreover, the combination treatment of MR-2088 with known KRAS→RAF→MEK→ERK pathway inhibitors, such as trametinib, showed promising synergistic effect in vitro using H2030 (KRAS) cell lines. Lastly, our findings underscore MR-2088's potential to inhibit starvation/stimuli-induced autophagic flux, coupled with its suitability for in vivo studies based on its pharmacokinetic properties. PubMed: 38232465DOI: 10.1016/j.ejmech.2023.116101 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.3 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード